ESTRO 2025 - Abstract Book

S824

Clinical - Gynaecology

ESTRO 2025

Regarding vaginal toxicity 100% of patients treated with EBRT developed partial cleisis with no statistical association to IGBT. Patients who followed vaginal care instructions had significantly lower risk of cleisis, with only 1 in 25p developing it. Patients reported excellent QoL in the QLQ-C30 questionnaire with functional scores above 70% and symptom scores below 35% (being the worst one fatigue at 32%). Global health status and QoL scale was 71%. EN24 questionnaire functional symptom scores were below 38% (worst scores were muscular pain-38% and back pain 29%). Regarding SH, EN24 scores were around 18% (low score); SH22 questionnaire patients indicated 38% sexual activity, 22% pain, and 39% vaginal dryness; FSFI questionnaire average score was 10 (range 2-36), with higher scores reflecting better sexual function. FSM2 showed severe sexual dysfunction in most patients.